{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000036","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.927676+00:00","generated_at":"2026-06-12T07:47:26.812852+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale","bullets":["Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.","FILSPARI launch: 417 new patient start forms in Q2; net sales $3.5M in Q2, $6.5M since Feb approval.","Positive pegtibatinase Cohort 6 results: 67.1% mean tHcy reduction; Phase 3 study expected by year-end.","Agreement to sell bile acid portfolio (Cholbam, Chenodal) to Mirum for up to $445M ($210M upfront); close Q3 2023.","Cash $491.3M; topline confirmatory PROTECT data for IgAN sNDA expected late Q3/early Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000036","json":"https://secwatch.observer/filing/0001438533-23-000036.json","markdown":"https://secwatch.observer/filing/0001438533-23-000036.md","text":"https://secwatch.observer/filing/0001438533-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/tvtx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:47:26.812852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe105de4b06fa0f26c77529900582569f08707a3","claim":"Travere Therapeutics, Inc. reported the second quarter of 2023 results: revenue $59.7 million, net income $1.13 per basic share, EPS $1.13 per basic share.","evidence_excerpt":"treatment standards from pipeline and strengthens financial foundation; transaction expected to close in third quarter of 2023 • Total revenue for the second quarter of 2023 was $59.7 million, consisting of $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of June 30,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$59.7 million"},{"label":"Net income","value":"$1.13 per basic share"},{"label":"EPS","value":"$1.13 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}